TP53 and neoplasm: Further integrative analysis classified KRAS-mutant tumours into three subgroups based on co-mutations with STK11, TP53 and CDKN2A/B, each showing distinct genomic characteristics and potential treatment vulnerabilities, such as sensitivity to HSP90 inhibitors in KRAS/STK11 co-mutated LUAD cell lines [54].